Details for New Drug Application (NDA): 203857
✉ Email this page to a colleague
NDA 203857 describes GLATIRAMER ACETATE, which is a drug marketed by Mylan and Synthon Pharms Inc and is included in four NDAs. It is available from one supplier. Additional details are available on the GLATIRAMER ACETATE profile page.
The generic ingredient in GLATIRAMER ACETATE is glatiramer acetate. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.
The generic ingredient in GLATIRAMER ACETATE is glatiramer acetate. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.
Summary for 203857
| Tradename: | GLATIRAMER ACETATE |
| Applicant: | Synthon Pharms Inc |
| Ingredient: | glatiramer acetate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 203857
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;SUBCUTANEOUS | Strength | 20MG/ML | ||||
| Approval Date: | Sep 25, 2024 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
